Recent studies have shown that empagliflozin, a glucose cotransporter sodium-glucose cotransporter 2 inhibitor, is beneficial for treating neutropenia and neutrophil dysfunction in patients with GSD-Ib [24–26]. The gene discussed is SLC5A2; the disease is neutropenia.